rFVIII
Phase 3Biologic
rFVIII is one of 65 biologic programs targeting Von Willebrand disease. It is currently in Phase 3.
3
Indications
3
Total Trials
0
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
93 competitors in Hemophilia a
#DrugCompanyPhaseTrials
1Hemlibra
RochePhase 3
Recombinant Human Coagulation FVIII
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Eptacog Alfa
Novo NordiskPhase 3
Qfitlia
GGenzyme, a Sanofi Company
Phase 3
Valoctocogene Roxaparvovec
BioMarin PharmaceuticalPhase 3
Recombinant Factor VIII
BayerPhase 3
PF-06741086
PfizerPhase 3
Marstacimab
PfizerPhase 3
Rfviia
RochePhase 3
Refacto
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Von Willebrand disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rFVIII. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Pittsburgh